ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,392.61
0.46%
Dow Jones
39,259.01
0.52%
Gold vs US Dollar
2,329.785
0.94%
Brent Oil
83.685
0.15%
Bitcoin
61,415.45
0.37%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Palatin Technologies Inc New (PTN)

  7. Palatin Technologies Inc New (PTN) News

Palatin Technologies (PTN)

Palatin Technologies Inc New
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:PTN
DateTimeSourceHeadlineSymbolCompany
09/05/202412:30PR Newswire (US)Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024AMEX:PTNPalatin Technologies Inc New
02/05/202412:30PR Newswire (US)Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
30/04/202412:30PR Newswire (US)Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024AMEX:PTNPalatin Technologies Inc New
08/04/202412:30PR Newswire (US)Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024AMEX:PTNPalatin Technologies Inc New
07/03/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
04/03/202417:57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:PTNPalatin Technologies Inc New
28/02/202412:30PR Newswire (US)Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
15/02/202414:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
15/02/202412:30PR Newswire (US)Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
14/02/202421:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
14/02/202419:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:PTNPalatin Technologies Inc New
09/02/202412:30PR Newswire (US)Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024AMEX:PTNPalatin Technologies Inc New
05/02/202412:30PR Newswire (US)Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
01/02/202422:16Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
01/02/202421:00PR Newswire (US)Palatin Announces Closing of $10 Million Registered Direct OfferingAMEX:PTNPalatin Technologies Inc New
01/02/202414:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:PTNPalatin Technologies Inc New
30/01/202413:00PR Newswire (US)Palatin Announces $10 Million Registered Direct OfferingAMEX:PTNPalatin Technologies Inc New
08/01/202415:33PR Newswire (US)Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024AMEX:PTNPalatin Technologies Inc New
03/01/202413:00Business WireCosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.AMEX:PTNPalatin Technologies Inc New
20/12/202314:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
20/12/202312:30PR Newswire (US)Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 MillionAMEX:PTNPalatin Technologies Inc New
18/12/202321:45Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
18/12/202321:15PR Newswire (US)Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE AmericanAMEX:PTNPalatin Technologies Inc New
18/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:PTNPalatin Technologies Inc New
15/12/202321:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:PTNPalatin Technologies Inc New
08/12/202322:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
06/12/202322:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
06/12/202319:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:PTNPalatin Technologies Inc New
04/12/202322:00Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:PTNPalatin Technologies Inc New
01/12/202320:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:PTNPalatin Technologies Inc New
 Showing the most relevant articles for your search:AMEX:PTN

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
SCE
Surface Transforms
LSE
KEFI
Kefi Gold And Copper
LSE
BIRD
Blackbird
LSE
GOLD
LSE
ITV
Itv
LSE
PET
Petrel Resources
LSE
SYME
Supply@me Capital
LSE
GWMO
Great Western Mining
LSE
GCM
Gcm Resources
LSE
AAU
Ariana Resources
LSE
BOO
Boohoo
LSE
LLOY
Lloyds Banking
LSE
AGL
Angle
LSE
UPS
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved